Solid dispersion preparation

ABSTRACT

A granule or a tablet of a solid dispersion that allows a drug in a preparation to be rapidly dissolved without impairing dissolving of the solid dispersion, and a method for producing same is composed of 1 to 10% by weight of a poorly soluble drug, a water-soluble polymer, an excipient and 15 to 50% by weight if a disintegrator; a tablet of a solid dispersion composed of a poorly soluble drug, 1 to 5% by weight of a water-soluble polymer, an excipient and 15 to 50% by weight of a disintegrator; and a method for producing a granule or tablet of a solid dispersion comprising spraying a water-soluble polymer solution, in which a poorly soluble drug has been dispersed or dissolved, on a mixed powder of an excipient and a disintegrator, and granulating and drying a resultant.

CROSS REFERENCE TO RELATED APPLICATION

This application is a division of commonly owned, co-pending U.S. patentapplication Ser. No. 11/736,834, filed Apr. 18, 2007.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a solid preparation produced forimproving the dissolution of a poorly soluble drug, particularly to asolid preparation comprising a solid dispersion that can be rapidlydisintegrated and that allows a drug to be dissolved.

2. Description of the Related Art

Poorly soluble drugs have high crystallinity and extremely lowsolubility in water. Thus, bioavailability or internal absorption ofpreparations produced from these drugs is low so that there is a problemin that the drug action is insufficient. As a technique for addressingthis problem, a solid dispersion has been developed in which moleculesof a poorly soluble drug are dispersed in a polymer carrier such as acellulose derivative, in an amorphous state.

Conventional solid dispersions are used as preparations in the form ofcapsules containing a solid obtained by spray-drying a cosolvent inwhich a poorly soluble drug and a carrier are dissolved, or in the formof fine granules or granules as they are. The form of tablets, which isa generally used dosage form of solid preparations, is most preferablebecause tablets are easily prescribed and administered in a fixed dose,and easily handled and taken by patients.

It is known that in the case of tablets produced from a solid dispersionpowder, the porosity of the tablets is often lowered not only due to areduced specific surface area, but also due to plastic deformation ofamorphous drug molecules during a compression-molding process and strongbonding between carrier polymers. This low porosity leads to slowpermeation of water molecules into the tablets in administration, and toslow disintegration of the tablets, and thus the solid dispersion cannotexert its original effect of improving the dissolution. Furthermore, theviscosity of a water-soluble or enteric polymer serving as a carrierincreases during hydration or dissolution, and thus a type of hydrogellayer is formed on the surface of the tablets during dissolution, sothat water is further prevented from infiltrating.

As means for addressing these problems, Japanese Patent Application (PCTNational Phase) Unexamined Publication No. 2005-517690 has proposed atablet comprising a solid dispersion powder, a disintegrator and anexcipient comprising porosigen, and obtained by spray-drying.Furthermore, Japanese Patent Application Unexamined Publication No.5-262642/1993 has proposed a powder in which a water-soluble polymerbase and if necessary, an excipient and a disintegrator are added to apoorly soluble drug. However, an added amount of aconcentration-enhancing polymer or a water-soluble polymer base, servingas carriers, is large, and thus the rate at which a drug is dissolvedtends to be lowered. Furthermore, in the case of a solid dispersionpowder obtained by spray-drying as in Japanese Patent Application (PCTNational Phase) Unexamined Publication No. 2005-517690, it is necessarythat after the solid dispersion powder is mixed with the otheringredients, the mixture is compressed and pulverized for formation of agranulated powder for tableting. The particle size of the soliddispersion powder prepared by spray-drying in this manner is small, andthus when it is simply mixed with an excipient, segregation is caused sothat ingredients are not distributed uniformly in the powder fortableting. Moreover, this process makes the operation complicated, andthe solid dispersion may be recrystallized in compression. Furthermore,the disintegrator is added after the solid dispersion has been prepared,and thus when the solid dispersion is aggregated and bonded in thetablet due to high bonding strength of the carrier, aggregation may beformed and dispersed in water during disintegration, lowering thedissolution of the drug.

Japanese Patent Application Unexamined Publication No. 2004-67606 hasproposed a tablet comprising fine granules obtained by spraying asolution containing itraconazole, which is a poorly soluble drug, awater-soluble polymer and an enteric polymer, on a mixed powder of anexcipient and a disintegrator, granulating and drying the resultant.However, the amount of the disintegrator added is small and it takes aslong as 360 minutes for the drug to be dissolved from the tablet. Thus,the disintegratability of the tablet is not improved.

Hirasawa et al. (Journal of the Pharmaceutical Society of Japan, 124(1),19-23 (2004)) has proposed a tablet produced by loading an ethanoldispersion as a binding liquid containing nilvadipine which is a poorlysoluble drug, crospovidone and methylcellulose, into a mixed powder ofmaterials such as lactose, methylcellulose and low-substitutedhydroxypropylcellulose, and agitating and granulating the mixture. Thenilvadipine is soluble in ethanol, but crospovidone and methylcelluloseare not soluble in ethanol. Thus, it seems that the ethanol functionsonly as an agent for dispersing and diluting amorphous nilvadipinebecause a co-dissolved state is not obtained. In order to disperseamorphous drug molecules in a polymer serving as a carrier, it isnecessary to obtain a co-dissolved state in a cosolvent in which boththe drug molecules and the polymer are dissolved. Thus, it seems thatthe solid dispersion of amorphous nilvadipine described in Journal ofthe Pharmaceutical Society of Japan 124(1), 19-23 (2004) does not havesufficient solubility. Furthermore, since an amount of water-solublepolymer added is large, it may be difficult to obtain a preparation thatcan be rapidly dissolved.

SUMMARY OF THE INVENTION

The present invention was reached in view of the above-describedcircumstances, and it is an object thereof to provide a granule or atablet of a solid dispersion that allows a drug in a preparation to berapidly dissolved without impairing the dissolution of the soliddispersion, and a method for producing the same.

The inventors had conducted an in-depth study in order to address theabove-described problem, and found that when a water-soluble polymerserving as a carrier of a solid dispersion and a disintegrator are addedin predetermined amounts, respectively, disintegratability is notlowered in tablets obtained by compression-molding the solid dispersion,and granules and tablets have excellent solubility. Thus, the presentinvention has been achieved.

More specifically, the present invention provides a granule of a soliddispersion comprising a poorly soluble drug, a water-soluble polymer, anexcipient and a disintegrator, wherein a content of the water-solublepolymer is 1 to 10% by weight and a content of the disintegrator is 15to 50% by weight; a tablet of a solid dispersion comprising a poorlysoluble drug, a water-soluble polymer, an excipient and a disintegrator,wherein a content of the water-soluble polymer is 1 to 5% by weight anda content of the disintegrator is 15 to 50% by weight; and a method forproducing a granule or tablet of a solid dispersion comprising sprayinga water-soluble polymer solution in which a poorly soluble drug has beendispersed or dissolved, on a mixed powder of an excipient and adisintegrator, and granulating and drying the resultant.

According to the present invention, a solid preparation with excellentsolubility is obtained that has high solubility in the case of agranule, and that can be disintegrated and release at least 70% byweight of a poorly soluble drug within 10 minutes after the introductionto a dissolution medium in the case of a tablet.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Hereinafter, the present invention is described in more detail.

A poorly soluble drug used in the present invention has extremely lowsolubility in water, and poor absorption in ordinary oraladministration. For example, the poorly soluble drug means a drug thatis “practically insoluble or insoluble” or “very slightly soluble” asprescribed in the Japanese Pharmacopoeia Fourteenth Edition. The term“solubility” of a drug in the Japanese Pharmacopoeia Fourteenth Editionmeans the degree of dissolution of the drug, powdered in the case of asolid, within 30 minutes in a solvent at 20±5° C., by shaking for 30seconds each time at 5-minute intervals. If a drug is “practicallyinsoluble or insoluble”, then an amount of solvent (water, in thisspecification) required for dissolving 1 g or 1 ml of the drug is 10,000ml or more. If a drug is “very slightly soluble”, then an amount ofsolvent required for dissolving 1 g or 1 ml of the drug is 1,000 ml ormore and less than 10,000 ml.

Specific examples of the poorly soluble drug used in the presentinvention may include, but are not limited to, nifedipine, phenacetin,phenyloin, digitoxin, nilvadipine, diazepam, griseofulvin andchloramphenicol.

In the present invention, since molecules of a poorly soluble drug aredispersed in an amorphous state, a water-soluble polymer is used as acarrier. The water-soluble polymer is a polymer that is “very soluble(an amount of water required for dissolving 1 g or 1 ml of the drug isless than 1 ml)”, “freely soluble (an amount of water required fordissolving 1 g or 1 ml of the drug is 1 ml or more and less than 10ml)”, or “soluble (an amount of water required for dissolving 1 g or 1ml of the drug is 10 ml or more and less than 30 ml)” as prescribed inthe Japanese Pharmacopoeia Fourteenth Edition, when the polymer is addedto hot water (70° C. or higher) ranging from half to the total amountrequired for dissolution and the mixture is agitated and dispersed,while in a case that the amount of hot water used is less than the totalamount required cold water or ice water in the remaining amount is addedwith agitation. Specific examples thereof may include alkylcellulosesuch as methylcellulose; hydroxyalkylcellulose such ashydroxyethylcellulose and hydroxypropylcellulose;hydroxyalkylalkylcellulose such as hydroxyethylmethylcellulose andhydroxypropylmethylcellulose; polyvinyl alcohol; and polyvinylpyrrolidone. Of these, hydroxypropylmethylcellulose may be particularlypreferable.

The content of the water-soluble polymer may vary depending on thedosage form of the solid preparation. If the solid preparation is in theform of granule, then the preferable content may be 1 to 10% by weightwith respect to the total amount of the preparation. If the solidpreparation is in the form of tablet, then the preferable content may be1 to 5% by weight with respect to the preparation. If the content of thewater-soluble polymer is less than 1% by weight, then it may bedifficult to obtain a completely amorphous state of the poorly solubledrug in a solid dispersion. If the content is more than 10% by weight inthe case of granule, or more than 5% by weight in the case of tablet,then the portion of the water-soluble polymer in the preparation becomeslarge, which is not preferable because the dosage amount of the granuleor the size of the tablet may become large.

The weight ratio of the water-soluble polymer to the poorly soluble drugmay be preferably 1 to 5 when taking the poorly soluble drug as 1. Ifthe ratio of the water-soluble polymer is less than 1, then the poorlysoluble drug in the solid dispersion may not be in a completelyamorphous state. If the ratio is more than 5, then the ratio of thewater-soluble polymer in the preparation becomes large, and thus thesize of the preparation becomes large, which may not be suitable for agenerally used preparation.

The solvent for preparing the solid dispersion comprising thewater-soluble polymer and the poorly soluble drug may be preferably asolvent in which the poorly soluble drug is well dissolved and thewater-soluble polymer is also dissolved. Examples of the solvent mayinclude methanol, ethanol, methylene chloride, acetone, a mixturethereof and their mixed solvents with water. The solvent may be selectedappropriately based on the solubility of the poorly soluble drug and thewater-soluble polymer in the solvent.

The solvent may be added in an amount at which the solid concentrationis preferably 3 to 18% by weight, particularly preferably 3.5 to 12% byweight.

Examples of the excipient used in the present invention may includelactose, cornstarch, saccharose, mannite, anhydrous calcium phosphate,crystalline cellulose and their mixtures. It may be particularlypreferable to use a mixed powder comprising lactose and cornstarch in aweight ratio of 7:3.

The content of the excipient may be preferably 30 to 90% by weight,particularly preferably 42.5 to 78.5% by weight, with respect to thetotal amount of the preparation. If the content of the excipient is lessthan 30% by weight, then the amount of the disintegrator may become toolarge and thus the flowability of the granulated powder may be poor. Ifthe content is more than 90% by weight, then the amount of thedisintegrator becomes small, and thus an effect of improving solubilitymay not be expected.

Examples of the disintegrator used in the present invention may includecarmellose, carmellose sodium, carmellose calcium, croscarmellosesodium, low-substituted hydroxypropylcellulose (L-HPC) having 5 to 16%by weight of hydroxypropoxyl groups, hydroxypropyl starch, sodiumcarboxymethyl starch, crospovidone and their mixtures.

As the disintegrator used in the present invention, low-substitutedhydroxypropylcellulose may be particularly preferable because itprovides granulates with high flowability and ensures high dissolutionfrom the compression-molded preparation. The low-substitutedhydroxypropylcellulose having a loose bulk density of 0.40 g/ml or moreand a tapped bulk density of 0.60 g/ml or more may be particularlypreferable.

Herein, the term “loose bulk density” means the bulk density in aloosely filled state and is measured by uniformly supplying a samplefrom 23 cm above, through a sieve with 24 mesh of Japanese IndustrialStandards (JIS), to a cylindrical vessel of stainless steel having adiameter of 5.03 cm and a height 5.03 cm (volume 100 ml), and performingweighing after leveling at the upper surface. The term “tapped bulkdensity” means the bulk density in a tightly filled state obtained byperforming tapping on the vessel in the loosely filled state. Thetapping means an operation to make the sample be tightly filled, byrepeatedly dropping the vessel filled with the sample from apredetermined height thereby providing the bottom portion with a lightimpact. In practice, when weighing has been completed after leveling atthe upper surface in the measurement of the loose bulk density, a cap (acomponent of a powder tester manufactured by Hosokawa MicronCorporation) is placed on the vessel, powder is added to the upper edgeof the cap, and tapping is performed 180 times at a tapping height of1.8 cm. When the tapping has been completed, the cap is removed andweighing is performed after leveling the powder at the upper surface ofthe vessel. The bulk density in this state is taken as the tapped bulkdensity. These operations can be performed using a powder tester (PT-D)manufactured by Hosokawa Micron Corporation.

Furthermore, the low-substituted hydroxypropylcellulose having a degreeof compression of 35% or less may be preferable. Herein, the degree ofcompression means the degree of volume decreased and is obtained by thefollowing equation:

Degree of compression (%)={(tapped b.d.−loose b.d.)/tapped b.d.}×100

wherein b.d. means bulk density.

The content of the disintegrator may be preferably 15 to 50% by weight,particularly preferably 20 to 40% by weight, with respect to the totalamount of the preparation. If the content of the disintegrator is lessthan 15% by weight, then an effect of improving solubility may be weakand an expected effect may not be obtained. If the content is more than50% by weight, then the flowability of the obtained granule powder maybe lowered, which is not preferable for powder for tableting.

If necessary, a lubricant may be added to the tablet of the soliddispersion of the present invention. Examples of the lubricant mayinclude magnesium stearate, sucrose fatty acid ester, polyethyleneglycol, talc and stearic acid.

The amount of the lubricant may be preferably 0.5 to 2% by weight withrespect to the amount of the preparation excluding the lubricant. If theamount of the lubricant added is less than 0.5% by weight, thensufficient lubricative properties may not be obtained so that thepreparation may adhere to a mortar or a pestle during tableting. If theamount is more than 2% by weight, then hardness or disintegratabilitymay be lowered.

Next, methods for producing granules and tablets of the solid dispersionof the present invention will be described.

The granule of the solid dispersion of the present invention can beobtained by spraying a water-soluble polymer solution in which thepoorly soluble drug has been dispersed or dissolved, on a mixed powderof the excipient and the disintegrator, and granulating and drying theresultant. More specifically, the water-soluble polymer solution inwhich the poorly soluble drug has been dispersed or dissolved is sprayedon the mixed powder of the excipient and the disintegrator which isflowing in a granulator, the resultant is granulated and dried, and thenthe particle size regulation is carried out.

Examples of the granulator may include a fluidized bed granulationcoating device, a high speed agitation granulating device and a rollinggranulating device. The fluidized bed granulation coating device may beparticularly preferable.

Using the granules obtained by the above-described method as powder fortableting, the tablets of the present invention may be obtained byadding an optional lubricant to the granules and compression-molding thegranules in a tableting machine. The granules obtained by theabove-described method may be also pulverized by using an appropriatepulverizer before the tableting when the pulverization is needed forpowder properties, improvement of dissolution or the like. Thepulverizer may include a knife mill, a roller mill, a ball mill, a jetmill, a screening mil and a beads mill.

When the thus obtained granules of the solid dispersion are evaluatedfollowing “Dissolution Test, Method 2” described in the JapanesePharmacopoeia Fourteenth Edition, the concentration of the drugdissolved within 5 minutes after administration may be 70% or more withrespect to the dose. Thus, high dissolution is exhibited.

When the obtained tablets of the solid dispersion are evaluatedfollowing “Disintegration Test” described in the Japanese PharmacopoeiaFourteenth Edition, the tablets may be disintegrated within 10 minutesafter administration, and when the tablets are evaluated following“Dissolution Test, Method 2” described in the Japanese PharmacopoeiaFourteenth Edition, the concentration of the drug dissolved within 10minutes after administration may be 70% or more with respect to thedose. Thus, high disintegratability and high dissolution are exhibited.

The solid preparation obtained in the present invention may be coated byknown methods in order to provide taste-masking or odor-masking, to makethe preparation enteric, or to achieve sustained release of thepreparation. Examples of the coating agent may include enteric polymerssuch as cellulose acetate phthalate, methacrylic acid copolymer L,methacrylic acid copolymer LD, methacrylic acid copolymer S,hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcelluloseacetate succinate and carboxymethylethylcellulose; polymers soluble instomach such as polyvinyl acetal diethylaminoacetate and aminoalkylmethacrylate copolymer; and the water-soluble polymers described above.

Hereinafter, the present invention will be specifically described by wayof examples and comparative examples, but it should not be construedthat the present invention is limited to these examples.

Example 1 and Comparative Example 1

A solid dispersion solution was prepared by dissolving 1.2 g ofnifedipine and 2.4 g of hydroxypropylmethylcellulose (HPMC) (8.7% byweight of hydroxypropoxyl groups and 28.8% by weight of methoxyl groups,6 mPa·s), or 12 g of nifedipine and 24 g of hydroxypropylmethylcellulose(HPMC) (8.7% by weight of hydroxypropyl groups and 28.8% by weight ofmethoxyl groups, 6 mPa·s), in a mixed solvent containing ethanol andwater in a weight ratio of 8:2. The solid dispersion solution wassprayed on the mixture of low-substituted hydroxypropylcellulose (L-HPC)(10.9% by weight of hydroxypropoxyl groups), lactose (Pharmatosemanufactured by DMV International) and cornstarch (cornstarch Wmanufactured by Nihon Shokuhin Kako Co., Ltd.) which had been flowing ina fluidized bed granulation coating device (Multiplex MP-01 manufacturedby POWREX CORPORATION), and the resultant was granulated and dried. Thenthe particle size was regulated with a sieve of 30 mesh (opening: 500μm) to yield granules. As a comparative example, granules containing asa disintegrator the low-substituted hydroxypropylcellulose with theamounts outside of the range specified by the present invention wereproduced in a similar manner.

Table 1 shows results of the flowability evaluation when 20 g each ofthe obtained granules having various formulae was evaluated using theorifice flowability index. Herein, the orifice flowability index meansthe index for evaluating the flowability of powder and is obtained byplacing 20 g of sample in an hourglass-shaped funnel (inner diameter: 42mm, height: 90 mm) with its orifice blocked, allowing the sample to flowdown through the orifice, and evaluating the flowability based on theorifice size.

The evaluation “good” for flowability means good flowablity and rapidflow-down of the powder, while the evaluation “poor” means poorflowability and the powder did not flow down through the orifice.

TABLE 1 composition nifedipine HPMC L-HPC lactose cornstarch total (g)(g) (g) (g) (g) (g) flowability Example 1 formula A 1.2 2.4 48 131.956.5 240 good formula B 12 24 48 109.2 46.8 240 good formula C 12 24 9675.6 32.4 240 good Comp. Ex. 1 formula D 12 24 — 142.8 61.2 240 goodformula E 12 24 24 126 54 240 good formula F 12 24 144  42 18 240 poor

Example 2 and Comparative Example 2

Among the granules obtained in Example 1 and Comparative Example 1, 1890mg of granules (containing 94.5 mg of nifedipine) with good flowabilitywere tested in accordance with the Paddle method of the Dissolution Testin the Japanese Pharmacopoeia Fourteenth Edition. As the conditions forthe Dissolution Test, the rotational speed was set to 100 rpm, and 900ml of water was used as a test fluid. For the sake of reference, 94.5 mgof nifedipine powder alone was also tested in a similar manner. Table 2shows the results.

All of the granules (Formulae A to C) of Example 2 exhibited dissolutionhigher than that of the granules of Comparative Example 2. On the otherhand, Formula E in which the amount of the low-substitutedhydroxypropylcellulose serving as the disintegrator was smaller than therange specified by the present invention, exhibited the similar vales tothose obtained for Formula D in which the low-substitutedhydroxypropylcellulose was not added, and thus the solubility was notsubstantially improved. Formula F in which the amount of thelow-substituted hydroxypropylcellulose was large, blocking was causedduring fluidized bed granulation and thus it was difficult to performgood granulation.

As a result, it is evident that the granules of the solid dispersion ofthe present invention have excellent solubility.

TABLE 2 dissolution (%) time (minunites) 0 2 5 10 15 20 30 45 60 Ex. 2formula A 0 67.4 71.6 70.6 68.3 67.3 65.2 62.9 62.0 formula B 0 53.771.3 69.7 66.7 65.9 61.8 60.8 59.5 formula C 0 65.8 73.1 70.4 68.3 67.765.9 64.0 61.6 Comp. Ex. 2 formula D 0 46.9 59.8 61.2 59.8 58.2 57.054.9 54.1 formula E 0 56.5 58.2 60.2 59.0 57.4 55.3 54.1 52.3 formula F— — — — — — — — — nifedipine alone 0  0.6  3.4  9.3 10   10.6 11.9 11.911.9

Example 3 and Comparative Example 3

A solid dispersion solution was prepared by dissolving 1.2 g ofnifedipine and 2.4 g of hydroxypropylmethylcellulose (HPMC) (8.7% byweight of hydroxypropoxyl groups and 28.8% by weight of methoxylgroups), or 6 g of nifedipine and 12 g of hydroxypropylmethylcellulose(HPMC) (8.7% by weight of hydroxypropyl groups and 28.8% by weight ofmethoxyl groups), in a mixed solvent containing ethanol and water in aweight ratio of 8:2. The solid dispersion solution was sprayed on amixture of low-substituted hydroxypropylcellulose (L-HPC) (10.9% byweight of hydroxypropoxyl groups), lactose (Pharmatose manufactured byDMV International) and cornstarch (cornstarch W manufactured by NihonShokuhin Kako Co., Ltd.) which had been flowing in a fluidized bedgranulation coating device (Multiplex MP-01 manufactured by POWREXCORPORATION). The resultant was granulated and dried, and the particlesize was regulated with a sieve of 30 mesh (opening: 500 μm). Thus,granules were obtained. Using the granules as powder for tableting, 0.5%by weight of magnesium stearate as a lubricant was added to the powderfor tableting, mixing the resultant, and processing the mixture in arotary tableting machine (Vergo manufactured by Kikusui SeisakushoLtd.). As a result, 210 mg of tablets were produced. As a comparativeexample, tablets containing as a water-soluble polymer thehydroxypropylmethylcellulose with amounts outside of the range specifiedby the present invention were produced in similar manner. The obtainedtablets were tested in terms of hardness and disintegratability. Theresults are shown in Table 3.

The tablets (Formulae G to I) obtained in Example 3 exhibitedappropriate hardness and excellent disintegratability.

On the other hand, the tablets (Formulae J to L) obtained in ComparativeExample 3 containing as a water-soluble polymer thehydroxypropylmethylcellulose with amounts outside of the range specifiedby the present invention exhibited the lowered disintegratability.

TABLE 3 composition nifedipine HPMC L-HPC lactose cornstarch totalhardness distintegration time (g) (g) (g) (g) (g) (g) (kgf) (minutes)Example 3 formula G 1.2 2.4 48 131.9 56.5 240 7 4.3 formula H 6 12 48121.8 52.2 240 7.4 7.4 formula I 6 12 96 88.2 37.8 240 6.1 7.1 Comp. Ex.3 formula J 6 12 — 155.4 66.6 240 10 24.4 formula K 12 24 48 109.2 46.8240 10 21.6 formula L 12 24 96 75.6 32.4 240 9.4 25.3

Example 4 and Comparative Example 4

The Dissolution Test was conducted on 1890 mg of the tablets (containing47.25 mg of nifedipine) obtained in Example 3 and Comparative Example 3in the same manner as in Example 2. Furthermore, for the sake ofreference, 47.25 mg of nifedipine powder alone was also tested in asimilar manner. The results are shown in Table 4.

The tablets (Formulae G to I) obtained in Example 4 exhibiteddissolution results that were by no means inferior to that of thegranulated powder. Furthermore, the dissolution was improved byincreasing the amount of the disintegrator. The solubility was notsubstantially improved for Formula J in which the low-substitutedhydroxypropylcellulose serving as the disintegrator was not added.

On the other hand, for Formulae J and K containing as a water-solublepolymer the hydroxypropylmethylcellulose with the amount outside of therange specified by the present invention, hydrogel of the water-solublepolymer was formed on the surface of the tablets during the test andthus sustained release of letting dissolution start from the surface astime passed took place, so that extended disintegration time andinsufficient improvement of dissolution were observed as in conventionalexamples.

Thus, it is evident that the tablets of the solid dispersion of thepresent invention have excellent disintegratability and excellentsolubility.

TABLE 4 dissolution (%) time (minutes) 0 2 5 10 15 20 30 45 60 Example 4formula G 0 42.0 74.6 83.9 79.3 76.9 70.7 71.5 70.7 formula H 0 41.466.3 71.2 72.1 63.8 65.4 67.1 63.0 formula I 0 39.8 69.6 81.2 79.5 77.977.0 78.7 84.5 Comp. Ex. 4 formula J 0 7.5 21.8 42.8 50.3 49.5 52.8 51.150.3 formula K 0 7.6 17.1 25.4 31.2 33.1 35.0 35.9 36.6 formula L 0 9.217.8 25.9 30.4 33.2 35.4 39.9 39.1 nifedipine alone 0 0.6 3.4 9.3 1010.6 11.9 11.9 11.9

1. A granule of a solid dispersion comprising a poorly soluble drug, awater-soluble polymer, an excipient and a disintegrator, wherein acontent of the water-soluble polymer is 1 to 10% by weight and a contentof the disintegrator is 15 to 50% by weight.
 2. The granule of the soliddispersion according to claim 1, wherein the water-soluble polymer isselected from the group consisting of alkylcellulose,hydroxyalkylcellulose, hydroxyalkylalkylcellulose, polyvinyl alcohol andpolyvinyl pyrrolidone.
 3. The granule of the solid dispersion accordingto claim 1 or 2, wherein the disintegrator is low-substitutedhydroxypropylcellulose having 5 to 16% by weight of hydroxypropoxylgroups.
 4. The granule of the solid dispersion according to claim 3,wherein the disintegrator is low-substituted hydroxypropylcellulosehaving a loose bulk density of at least 0.40 g/ml and a tapped bulkdensity of at least 0.60 g/ml.